Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
NCT03870763 · Biogen · PHASE3 · terminated · last registry update 2023-06-15 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Decision to stop the trial was based on long-term difficulties in fulfilling our enrolment commitments and changes in paediatric MS landscape which no longer support placebo-controlled trials.Decision to stop study was not based on safety concerns.” | – | Registry record, Biogen |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KEAP1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-06-11Results posted on the registry: Biogen, Bardoxolone methyl oral capsule + Placebo oral capsule (NCT03918447)
- 2024-03-27Also stopped (terminated): GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03446612)
- 2024-03-19Results posted on the registry: Biogen, Bardoxolone methyl (NCT03749447)
- 2023-12-15Results posted on the registry: The Methodist Hospital Research Institute, L-NMMA + Docetaxel (NCT02834403)
- 2023-10-27Also stopped (terminated): Biogen, 20 mg bardoxolone methyl + Placebo (NCT01500798)
- 2023-10-12Results posted on the registry: Biogen, Bardoxolone methyl (NCT03068130)
- 2023-10-11Results posted on the registry: Biogen, Placebo Oral Capsule + Bardoxolone Methyl (NCT03019185)
- 2023-09-26Also stopped (terminated): Kyowa Kirin Co., Ltd., Bardoxolone methyl + Placebo (NCT03550443)
- 2023-08-24Results posted on the registry: Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT03606174)
- 2023-08-24Also stopped (terminated): Mirati Therapeutics Inc., Sitravatinib + Nivolumab (NCT03606174)
- 2023-05-19Results posted on the registry: Biogen, Placebo capsules + Bardoxolone methyl capsules (NCT02657356)
- 2023-03-06Phase 3 first posted: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502) + Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) (NCT05755048)
- 2022-12-01Results posted on the registry: Biogen, Bardoxolone methyl oral capsule + Placebo oral capsule (NCT04702997)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision